Thrombocytopenia-Absent Radius Syndrome
- Author: John K Wu, MBBS, MSc, FRCP(C); Chief Editor: Robert J Arceci, MD, PhD more...
Background
Thrombocytopenia-absent radius (TAR) syndrome is a rare condition in which thrombocytopenia is associated with bilateral radial aplasia. TAR syndrome was first described in 1951. An autosomal recessive inheritance pattern was proposed because TAR affected more than one member of some families. In 1969, TAR was defined as a syndrome and further classified as the association of hypomegakaryocytic thrombocytopenia and absent radii. The expression varies and includes abnormalities in the GI, skeletal, hematologic, and cardiac systems. See the images below.
Infant with thrombocytopenia-absent radius syndrome. The arms and forearms are shortened, with radial deviation of both hands because of the absence of bilateral radii. The legs are normal. See also Media files 2 and 3.
Same infant as in Media files 1 and 3. Close-up photograph of arm and forearm (volar aspect). Note the petechiae.
Same infant as in Media files 1 and 2. Close-up photograph of arm and forearm (dorsal aspect). Pathophysiology
Some have proposed that the association of seemingly disparate skeletal and hematologic abnormalities is related to the simultaneous development of the heart, the radii, and the megakaryocytes at 6-8 weeks' gestation. The similarity of TAR syndrome to congenital rubella suggests intrauterine injury when the involved systems develop, but a common etiologic agent has not been identified. As an alternative, the contiguous gene model is based on the premise that phenotypic findings are related when genes responsible for each defect are geographically related in a chromosome. This mechanism, if true, is independent of the anatomic association and the degree of involvement in either system.
The exact pathophysiology of the thrombocytopenia is still unclear. The platelet abnormality reflects platelet hypoproduction, for which numerous explanatory theories have been proposed. One suggestion is that a failure in production of humoral or cellular stimulators of megakaryocytopoiesis (eg, thrombopoietin) is responsible for inhibiting platelet production. However, studies by Ballmaier and colleagues and Sekine and associates showed comparable or increased levels of thrombopoietin in patients with TAR compared with healthy control subjects.[1, 2] These findings suggest that the thrombocytopenia is due to a lack of response to thrombopoietin, especially given the observation of normal thrombopoietin receptor expression on megakaryocytes. Letestu and colleagues suggested that the defect was a blockage in cell differentiation at an early stage.[3]
Other theories for platelet hypoproduction include an abnormal response to stimulators of megakaryocytopoiesis involving an abnormal signal-transduction pathway, decreased numbers and sizes of megakaryocytic progenitor cells,[2] abnormal progenitor cells with a maturational defect or receptor defect, and the presence of humoral or cellular inhibitors of megakaryocytopoiesis.
No causative mutation has been identified despite investigations of the c-mpl gene in patients with TAR.[4] Another proposed candidate gene is a HOX gene. The HOX family of genes plays a major role in embryogenesis and cell differentiation, including differentiation of hematopoietic cell lines. However, Fleischman and colleagues did not detect mutations in the coding sequence of HOX genes known to affect radial development.[5] An interstitial microdeletion of chromosome 1q was identified in 30 patients with TAR syndrome.[6] All patients and 75% of unaffected parents in this cohort had the microdeletion, suggesting co-inheritance of an additional modifier gene for disease expression. The observation that platelet counts improve during infancy and that they may even normalize with age has led to the suggestion that abnormal genes may be developmentally regulated.
TAR syndrome is generally considered an autosomal recessive disease. Some have suggested that the inheritance pattern may be autosomal dominant with variable penetrance. Urban and associates postulated that, given the phenotypic overlap between Roberts syndrome and TAR syndrome, allelic heterogeneity might cause both. In this postulate, TAR syndrome is the compound heterozygous form, with a mild and a severe mutation, whereas Roberts syndrome is the homozygous form with the severe mutation. However, genetic heterogeneity and environmental factors cannot be completely ruled out.
Epidemiology
Frequency
United States
TAR syndrome rarely occurs in the United States.
International
The frequency of TAR syndrome is 0.42 case per 100,000 live births in Spain.
Mortality/Morbidity
The major cause of mortality in TAR syndrome is hemorrhage. The incidence of hemorrhage is limited to the first 14 months of life. In a study by Hedberg and associates, 18 of 20 deaths in 76 patients were due to hemorrhagic events; most of patients who died had platelet counts < 10 X 109/L.[7]
Bleeding and hemorrhage can also result in clinically significant morbidity, especially intracranial hemorrhage. Hand and upper-extremity function is usually good if radial aplasia is the only skeletal abnormality. However, patients require plastic surgery, occupational therapy, and physiotherapy.
Race
No ethnic or racial predilection is reported.
Sex
The male-to-female ratio is 1:1. Greenhalgh and associates reported an excess of females (27:7),[8] as did Hall and colleagues (26:14).[9]
Age
TAR syndrome is congenital, and patients usually present with symptomatic thrombocytopenia in the first week of life.
Ballmaier M, Schulze H, Strauss G, et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood. Jul 15 1997;90(2):612-9. [Medline]. [Full Text].
Sekine I, Hagiwara T, Miyazaki H, et al. Thrombocytopenia with absent radii syndrome: studies on serum thrombopoietin levels and megakaryopoiesis in vitro. J Pediatr Hematol Oncol. Jan-Feb 1998;20(1):74-8. [Medline].
Letestu R, Vitrat N, Masse A, et al. Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood. Mar 1 2000;95(5):1633-41. [Medline]. [Full Text].
Geddis AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol Clin North Am. Apr 2009;23(2):321-31. [Medline].
Fleischman RA, Letestu R, Mi X, et al. Absence of mutations in the HoxA10, HoxA11 and HoxD11 nucleotide coding sequences in thrombocytopenia with absent radius syndrome. Br J Haematol. Feb 2002;116(2):367-75. [Medline].
Klopocki E, Schulze H, Strauss G, et al. Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome. Am J Hum Genet. Feb 2007;80(2):232-40. [Medline].
Hedberg VA, Lipton JM. Thrombocytopenia with absent radii. A review of 100 cases. Am J Pediatr Hematol Oncol. Spring 1988;10(1):51-64. [Medline].
Greenhalgh KL, Howell RT, Bottani A, et al. Thrombocytopenia-absent radius syndrome: a clinical genetic study. J Med Genet. Dec 2002;39(12):876-81. [Medline]. [Full Text].
Hall JG, Levin J, Kuhn JP, et al. Thrombocytopenia with absent radius (TAR). Medicine (Baltimore). Nov 1969;48(6):411-39. [Medline].
Sachdev P. Brief psychosis in thrombocytopenia-absent radius syndrome: a case report. Aust N Z J Psychiatry. Sep 2005;39(9):841-2. [Medline].
Skorka A, Bielicka-Cymermann J, Gieruszczak-Bialek D, Korniszewski L. Thrombocytopenia-absent radius (tar) syndrome: a case with agenesis of corpus callosum, hypoplasia of cerebellar vermis and horseshoe kidney. Genet Couns. 2005;16(4):377-82. [Medline].
Weinblatt M, Petrikovsky B, Bialer M, et al. Prenatal evaluation and in utero platelet transfusion for thrombocytopenia absent radii syndrome. Prenat Diagn. Sep 1994;14(9):892-6. [Medline].
Dempfle CE, Burck C, Grutzmacher T et al. Increase in platelet count in response to rHuEpo in patient with thromboctopenia and absent radii syndrome. Blood. 2001;97 (7):2189-90. [Medline]. [Full Text].
Aquino VM, Mustafa MM, Vackus L et al. Recombinant interleukin-6 in the treatment of congenital thrombocytopenia associated with absent radii. J Pediatr Hematol Oncol. 1998;20 (5):474-6. [Medline].
Fadoo Z, Naqvi SM. Acute myeloid leukemia in a patient with thrombocytopenia with absent radii syndrome. J Pediatr Hematol Oncol. Feb 2002;24(2):134-5. [Medline].
[Guideline] Finnish Medical Society Duodecim. Thrombocytopenia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Apr 27. [Full Text].
MacDonald MR, Schaefer GB, Olney AH, Patton DF. Hypoplasia of the cerebellar vermis and corpus callosum in thrombocytopenia with absent radius syndrome on MRI studies. Am J Med Genet. Mar 1 1994;50(1):46-50. [Medline].
McLaurin TM, Bukrey CD, Lovett RJ, Mochel DM. Management of thrombocytopenia-absent radius (TAR) syndrome. J Pediatr Orthop. May-Jun 1999;19(3):289-96. [Medline].
Urban M, Opitz C, Bommer C, et al. Bilaterally cleft lip, limb defects, and haematological manifestations: Roberts syndrome versus TAR syndrome. Am J Med Genet. Sep 23 1998;79(3):155-60. [Medline].

